Page 63 - Read Online

Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50 Page 153

+
+
62. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1 /CD11b myeloid
suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21. DOI
PubMed
63. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model
using CTLA-4 blockade. Cancer Res 2000;60:2444-8. PubMed
64. Hiura T, Kagamu H, Miura S, et al. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph
nodes during tumor progression. J Immunol 2005;175:5058-66. DOI
+
65. Tang S, Moore ML, Grayson JM, Dubey P. Increased CD8 T-cell function following castration and immunization is countered by
parallel expansion of regulatory T cells. Cancer Res 2012;72:1975-85. DOI PubMed PMC
66. Vergati M, Cereda V, Madan RA, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-
versus post-vaccination. Cancer Immunol Immunother 2011;60:197-206. DOI PubMed PMC
+ +
67. Derhovanessian E, Adams V, Hähnel K, et al. Pretreatment frequency of circulating IL-17 CD4 T-cells, but not Tregs, correlates
with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009;125:1372-9. DOI
68. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9:353-63. DOI
PubMed PMC
69. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-22. DOI PubMed
70. Ruan H, Bao L, Tao Z, Chen K. Flightless I homolog reverses enzalutamide resistance through PD-L1-mediated immune evasion in
prostate cancer. Cancer Immunol Res 2021;9:838-52. DOI PubMed
71. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J
Urol 1991;145:907-23. DOI PubMed
72. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91. DOI PubMed
73. Freedland SJ, Hotaling JM, Fitzsimons NJ, et al. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and
radical prostatectomy outcomes-results from the SEARCH database. Eur Urol 2008;53:758-64; discussion 765. DOI
74. Xue B, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate
1997;30:73-8. DOI PubMed
75. Correale P, Nieroda C, Zaremba S, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from
prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300. DOI
76. Perambakam S, Xue BH, Sosman JA, Peace DJ. Induction of Tc2 cells with specificity for prostate-specific antigen from patients
with hormone-refractory prostate cancer. Cancer Immunol Immunother 2002;51:263-70. DOI PubMed
77. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte
epitope of human prostate-specific antigen. Clin Cancer Res 2002;8:41-53. PubMed
78. Heiser A, Dahm P, Yancey DR, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate
prostate-specific CTL responses in vitro. J Immunol 2000;164:5508-14. DOI
79. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed
against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94. DOI PubMed
80. Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K. Prostate-specific antigen-derived epitopes capable of
+
inducing cellular and humoral responses in HLA-A24 prostate cancer patients. Prostate 2003;57:152-9. DOI PubMed
b
81. Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLA-A2402/K transgenic mice. Int J Cancer 2002;100:565-70. DOI
PubMed
82. Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T
cells. Clin Exp Immunol 1998;114:166-72. DOI PubMed PMC
83. Matsueda S, Takedatsu H, Yao A, et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3
supertype alleles. Clin Cancer Res 2005;11:6933-43. DOI
84. Klyushnenkova EN, Link J, Oberle WT, et al. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific
antigen. Clin Cancer Res 2005;11:2853-61. DOI
85. Mahadevan M, Liu Y, You C, et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of
dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother 2007;56:1615-24. DOI
86. Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al. Androgen ablation augments human HLA2.1-restricted T cell responses
to PSA self-antigen in transgenic mice. Prostate 2010;70:1002-11. DOI PubMed PMC
87. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
Cancer Cell 2005;7:239-49. DOI PubMed PMC
88. Cornford P, van den Bergh RCN, Briers E, et al. Eau-Eanm-Estro-Esur-Siog guidelines on prostate cancer. Part II-2020 update:
treatment of relapsing and metastatic prostate cancer. Eur Urol 2021;79:263-82. DOI
89. Just J, Osgun F, Knight C. Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise? Br J Gen
Pract 2018;68:541-2. DOI PubMed PMC
90. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue
extracts and body fluids. Int J Cancer 1995;62:552-8. DOI PubMed
91. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate specific membrane antigen. Cancer Res
1994;54:1807-11. PubMed